Bictegravir, a novel integrase inhibitor for the treatment of HIV infection.
J.D Zeuli, Stacey A. Rizza, Ramona Bhatia, Zelalem Temesgen
págs. 669-682
Binimetinib, encorafenib and cetuximab (BEACON Trial) combination therapy for patients with BRAF V600E-mutant metastatic colorectal cancer.
Faisal Shahjehan, Saivaishnavi Kamatham, Chandrikha Chandrasekharan, Pashtoon Murtaza Kasi
págs. 683-693
Eptinezumab for the treatment of migraine.
Damiana Scuteri, Maria Tiziana Corasaniti, Paolo Tonin, Giacinto Bagetta
págs. 695-703
Fexinidazole for the treatment of human African trypanosomiasis.
Alan H. Fairlamb
págs. 705-712
International Society for Pharmacoeconomics and Outcomes Research (ISPOR) (November 4-6, 2019 – Copenhagen, Denmark).
Alexandra Kibble
págs. 713-718
New product intros [brolucizumab, elexacaftor/tezacaftor/ivacaftor (new combination), fedratinib hydrochloride, glucagon (new formulation), pretomanid, rifamycin (new indication/new formulation), ropeginterferon alfa-2b, roxadustat (first-in-class), STR-01, treosulfan (new indication)].
págs. 719-722
© 2001-2024 Fundación Dialnet · Todos los derechos reservados
Coordinado por: